Fetal sex-specific differences in gestational age at delivery in pre-eclampsia : a meta-analysis by Schalekamp-Timmermans, Sarah et al.
Women’s Health
Fetal sex-specific differences in gestational age
at delivery in pre-eclampsia: a meta-analysis
On behalf of the Global Pregnancy Collaboration: Sarah Schalekamp-
Timmermans1*, Lidia R Arends,2 Elin Alsaker,3 Lucy Chappell,4
Stefan Hansson,5 Nina K Harsem,6 Maya J€almby,7
Arundhathi Jeyabalan,8 Hannele Laivuori,9 Debbie A Lawlor,10
Corrie Macdonald-Wallis,10 Per Magnus,3 Jenny Myers,11 Jørn Olsen,12
Lucilla Poston,4 Christopher W Redman,13 Anne C Staff,14 Pia Villa,15
James M Roberts16 and Eric A Steegers1
1Erasmus Medical Centre, Department of Obstetrics and Gynecology, Rotterdam, The Netherlands,
2Institute of Psychology, and Department of Pedagogical Sciences, Erasmus University Rotterdam,
Rotterdam, The Netherlands, and Erasmus Medical Centre, Department of Biostatistics, Rotterdam,
The Netherlands, 3Norwegian Institute of Public Health, Oslo, Norway, 4Women’s Health Academic
Centre, King’s College London and King’s Health Partners, London, UK, 5Lund University, Department of
Clinical Sciences, Obstetrics and Gynecology, Lund, Sweden, and Ska˚ne University Hospital, Perinatal
Unit, Malmo, Sweden, 6Oslo University Hospital, Department of Obstetrics, Oslo, Norway, 7Lund
University, Department of Clinical Sciences, Obstetrics and Gynecology, Lund, Sweden, and Ska˚ne
University Hospital, Department of Obstetrics and Gynecology, Malmo, Sweden, 8University of
Pittsburgh School of Medicine, Division of Maternal-Fetal Medicine, Department of Obstetrics,
Gynecology, and Reproductive Sciences, Pittsburgh, PA, USA, 9Medical and Clinical Genetics and
Obstetrics and Gynecology, and Institute for Molecular Medicine Finland, University of Helsinki,
Helsinki, Finland, 10MRC Integrative Epidemiology Unit at the University of Bristol, School of Social and
Community Medicine, Bristol, UK, 11Maternal & Fetal Health Research Centre, Manchester Academic
Health Science Centre, University of Manchester, Manchester, UK, 12Aarhus University, Institute of
Clinical Epidemiology, Aarhus, Denmark, and UCLA Los Angeles, Los Angeles, CA, USA, 13Nuffield
Department of Obstetrics and Gynecology, John Radcliffe Hospital, Oxford, UK, 14Oslo University
Hospital, Department of Obstetrics and Department of Gynecology, University of Oslo, Oslo, Norway,
15Obstetrics and Gynecology, and Clinical Graduate School in Pediatrics and Obstetrics/Gynecology,
University of Helsinki, Helsinki, Finland, 16Department of Obstetrics, Gynecology and Reproductive
Sciences, Epidemiology and Clinical and Translational Research University of Pittsburgh, Pittsburgh,
PA, USA
*Corresponding author. Erasmus MC. Room NA-29-24k. POB 2040, 3000CA Rotterdam, The Netherlands. E-mail:
s.timmermans@erasmusmc.nl
Accepted 27 May 2016
Abstract
Background: Pre-eclampsia (PE) is a major pregnancy disorder complicating up to 8% of
pregnancies. Increasing evidence indicates a sex-specific interplay between the mother,
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placenta and fetus. This may lead to different adaptive mechanisms during pregnancy.
Methods: We performed an individual participant data meta-analysis to determine asso-
ciations of fetal sex and PE, with specific focus on gestational age at delivery in PE. This
was done on 219 575 independent live-born singleton pregnancies, with a gestational
age at birth between 22.0 and 43.0 weeks of gestation, from 11 studies participating in a
worldwide consortium of international research groups focusing on pregnancy.
Results: Of the women, 9033 (4.1%) experienced PE in their pregnancy and 48.8% of the
fetuses were female versus 51.2% male. No differences in the female/male distribution
were observed with respect to term PE (delivered 37 weeks). Preterm PE (delivered<37
weeks) was slightly more prevalent among pregnancies with a female fetus than in preg-
nancies with a male fetus [odds ratio (OR) 1.11, 95% confidence interval (CI) 1.02–1.21].
Very preterm PE (delivered<34 weeks) was even more prevalent among pregnancies
with a female fetus as compared with pregnancies with a male fetus (OR 1.36, 95% CI
1.17–1.59).
Conclusions: Sexual dimorphic differences in the occurrence of PE exist, with preterm PE
being more prevalent among pregnancies with a female fetus as compared with preg-
nancies with a male fetus and with no differences with respect to term PE.
Key words: Sexual dimorphism, pre-eclampsia, placenta, sex ratio, ALSPAC
Introduction
There are known large sex differences in disease incidence,
presentation, diagnosis and outcome to treatment.1 During
past years attention has focused on the female/male distri-
bution during pregnancy and its interaction with maternal
health. Apparently, maternal physiological functions are
influenced in a fetal sex-specific manner during preg-
nancy.2 Pre-eclampsia (PE) is a major pregnancy disorder
complicating up to 8% of pregnancies in some countries.
PE is an important contributor to maternal and perinatal
morbidity and mortality worldwide.3 Pre-eclamptic
women as well as their children have an increased risk to
develop cardiovascular disease and stroke later in life.4 A
previous study indicated that fetal sex influenced gesta-
tional age at delivery in a Norwegian population from up
to 50 years ago, with female fetuses predominating in
pre-eclamptic pregnancies ending before 37 weeks.5
Gestational age has been suggested as an indicator of sub-
sets of PE with a different pathophysiology and with differ-
ent acute and long-range outcomes for both mother and
baby. Therefore, in this study we sought to confirm and ex-
tend these earlier findings to very preterm pregnancies in a
more diverse and contemporary pregnancy population. To
assess sex-specific differences in gestational age at delivery
in pre-eclamptic pregnancies, we conducted a meta-
analysis of individual data from 219 575 pregnant women
participating in 11 studies from several European,
Oceanian and US centres.
Material and Methods
Inclusion criteria and participating cohorts
In 2011, the Global Pregnancy Collaboration (CoLab)
was established to facilitate data and sample sharing be-
tween research groups studying PE and other pregnancy
disorders [pre-empt.cfri.ca/Collaboration/global-pregnancy-
Collaboration]. CoLab is a consortium of international re-
search groups with data and biological samples from
women before, during and in some cases long after preg-
nancy. Information on clinical data and samples is offered
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in a membership-wide shared database and available to
CoLab members and to investigators sponsored by
CoLab members.6 In 2012, we invited principal investi-
gators of international research groups active in CoLab
to participate in the current study. Studies participated
if they included pregnant women with available infor-
mation on the occurrence of PE. Information on gesta-
tional age at birth and fetal sex also had to be available.
Only live-born singleton pregnancies with a gestational
age at birth between 22.0 and 43.0 weeks of gestation
were included. Both nulliparous and multiparous
women could participate. Eleven studies agreed to par-
ticipate, comprising 219 575 independent singleton
pregnancies that met the inclusion criteria.7–16 The stud-
ies varied in sample size as well as study design, includ-
ing both low- and high-risk pregnancies. Study-specific
information with references to detailed information
about each individual study is shown in Table 1. All
studies were approved by the national, regional and
local relevant research review boards. Regarding the
ALSPAC study, ethical approval for the study was ob-
tained from the ALSPAC Ethics and Law Committee
and the local research ethics committees. All partici-
pants provided written informed consent for use of their
data. Anonymized data sets were stored on a single cen-
tral secured data server with access for the main analysts
only. MOOSE guidelines for reporting a meta-analysis
were followed.
Pre-eclampsia
Information on PE per study was obtained per participat-
ing centre by using measurements, medical registries, hos-
pital records and/or specific questionnaires. Gestational
hypertension was defined as a blood pressure >
140 mmHg systolic or > 90 mmHg diastolic in a woman
who was normotensive before 20 weeks’ gestation without
concurrent new-onset proteinuria. In all studies participat-
ing in CoLab and in this study, PE is defined according to
former International Society for the Study of Hypertension
in Pregnancy criteria (de novo gestational hypertension
with concurrent new-onset proteinuria [ 0.3 g protein in
a 24-h specimen, correlating with 30 mg/dl ( 1 þ read-
ing on dipstick) in a random urine determination with no
evidence of urinary tract infection].17 Superimposed PE
was defined as chronic hypertension diagnosed before
pregnancy or in the first 20 weeks of pregnancy, compli-
cated by de novo proteinuria occurring after gestational
week 20, in the absence of renal disease and urinary tract
infection. As PE is a syndrome that does not necessarily
present as de novo hypertension and proteinuria the same
day, and as routine antenatal follow-up schedules differTa
b
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between countries and pregnancies, the time of PE diagno-
sis is difficult to define precisely. Instead, gestational age at
delivery was used as a proxy for the onset of disease.
Women with a very early onset of PE (before gestational
week 34) often present with combined intrauterine growth
restriction (IUGR) or rapidly increasing maternal symp-
toms and rarely remain undelivered for many days or
weeks. Women with term PE (from gestational week 37 þ
0) are likely to be induced (provided vaginal delivery is
feasible and clinically justified) and delivered shortly after
diagnosis, complying with current international clinical PE
guidelines. As gestational age at delivery was reliably regis-
tered in the centres that were included in this analysis, this
was used as a proxy to distinguish between term, preterm
and very preterm PE (i.e. delivery 37 þ 0 weeks of gesta-
tion, < 37 weeks of gestation and < 34 weeks of gesta-
tion). This distinction between early and very early versus
term ‘onset’ of PE is a commonly used categorization in PE
studies.
Covariates
Information about maternal characteristics (maternal age,
parity, body mass index and the presence of chronic hyper-
tension) and birth characteristics (gestational age at birth,
offspring birthweight and fetal sex) in each study was ob-
tained per participating centre by using measurements,
medical registries, hospital records and/or specific
questionnaires.
Statistical analyses
Individual datasets were integrated into one central data-
base. For the cleaning of the central database the following
criteria were used: values had to be within three standard
deviations at either side of the mean and/or values had to
be clinically reasonable. Random-effects models as pro-
posed by DerSimonian and Laird were used to take the po-
tential between-study variation next to the within-study
variation into account.18,19 In this model, the inverse of
standard errors from the individual studies combined with
the between-study variation were used as weights.
Heterogeneity was assessed by the I2 index. The I2 index
describes the proportion of total variation in the effect sizes
that is due to heterogeneity between studies. To determine
the influence of any particular cohort on overall results, we
repeated each meta-analysis, leaving out one cohort at a
time (leave-one-out methodology). The overall effects are
presented as forest plots with the pooled odds ratios from
the random-effects models with 95% confidence intervals
(CI). Statistical analyses were performed with SAS 9.2
software (SAS Institute, Cary, NC) and Comprehensive
Meta-Analysis 2.0 (Biostat, Englewood, USA).
Results
Subject characteristics
Study-specific information about maternal and birth char-
acteristics is shown in Table 2. The overall distribution of
female and male fetuses was 48.8% versus 51.2%. The
overall prevalences of gestational hypertension and PE
were 2.9% and 4.1% (n¼ 6150 and n¼ 9033), respect-
ively. Of the pre-eclamptic women, 6.4% had superim-
posed PE (n¼575). Of the remaining 8458 de novo pre-
eclamptic women, 15.4% were diagnosed with very pre-
term PE (<34 weeks of gestation, n¼ 1306).
Pre-eclampsia and fetal sex
In this meta-analysis we observed no differences in the dis-
tribution of female versus male fetuses in the overall occur-
rence of PE (Figure 1). Furthermore, no differences in the
distribution of female versus male fetuses with respect to
de novo PE, superimposed PE or gestational hypertension
were observed. We observed no differences in the female/
male distribution with respect to term de novo PE
(i.e. 37 weeks of gestation) (Figure 2). After stratification
into preterm and very preterm de novo PE (i.e. < 37 weeks
of gestation and < 34 weeks of gestation), differences in
the distribution of female versus male fetuses in the occur-
rence of PE were observed. Female preterm PE was more
prevalent than male preterm PE in pregnancies going be-
yond 22.0 weeks (OR 1.11, 95% CI 1.02–1.21,
I2¼ 32.7%) (Figure 3). These results did not change after
applying the leave-one-out method nor did restriction of
these analyses to nulliparous women change the results.
Very preterm PE was even more prevalent among pregnan-
cies with a female fetus as compared with pregnancies with
a male fetus (OR 1.36, 95% CI 1.17–1.59, I2¼ 21.0%)
(Figure 4). Applying the leave-one-out method did not
change the results nor did restriction of these analyses to
nulliparous women (Supplementary Figures 1 and 2, avail-
able as Supplementary data at IJE online). Finally, no dif-
ferences in the female/male distribution with respect to de
novo PE between 34 and 37 weeks of gestation were
observed. This suggests that the effects with respect to pre-
term PE are mainly determined by effects in the distribu-
tion of female versus male fetuses in very preterm PE
(Supplementary Figure 3, available as Supplementary data
at IJE online).
International Journal of Epidemiology, 2017, Vol. 46, No. 2 635
Comment
Results from this large-scale meta-analysis of individual
participants’ data show sexual dimorphic differences in the
rates of PE subgroups, with preterm and very preterm PE
being more prevalent among pregnancies with a female
fetus as compared with pregnancies with a male fetus, and
with no differences with respect to term PE. No differences
in female/male distribution are observed in the overall risk
of PE.
Comparison with earlier studies and
interpretation of main findings
PE has a deleterious impact on maternal and fetal morbid-
ity, mortality and future health. It is a heterogeneous dis-
order with a complex aetiology and pathogenesis. Progress
in the understanding of the disorder would be assisted
greatly if subtypes could be characterized.20 Despite
increasing evidence that maternal physiological functions
are influenced in a fetal sex-specific manner during
pregnancy, in most studies that assess potential patho-
physiological mechanisms of PE, fetal sex has not been
taken into account.
Previously, a large Norwegian population-based data
study suggested that the sex ratio in PE displays a pattern
strongly dependent on length of gestation.5 They showed
that female babies were more frequent in PE with preterm
delivery, whereas PE with term delivery was dominated by
male offspring. Interestingly, when only assessing normo-
tensive pregnancies, opposite results were observed with a
male predominance in preterm births.5 Our results on PE
are in line with theirs, indicating that fetal sex influences
gestational age at delivery in pre-eclamptic pregnancies.
These results are further supported by a recent study by
Broere-Brown et al.21 showing fetal sex-specific differences
in maternal vascular adaptation to pregnancy. They
observed sex-specific differences in Doppler measurements
of the uterine artery and sex-specific differences in both
systolic and diastolic blood pressure patterns throughout
pregnancy. Interestingly, differential effects according to
the presence or absence of the placental syndromes, en-
compassing PE, IUGR and preterm birth, were observed.
In pregnancies complicated by the placental syndromes
women pregnant with a female fetus showed a higher
blood pressure compared with women with a male fetus at
the beginning of pregnancy. In contrast, by the end of the
second trimester a shift in the male blood pressure pattern
and female blood pressure pattern was observed. This re-
sulted in a higher blood pressure for women with a male
fetus compared with women with a female fetus at the end
of pregnancy.21
Table 2. Maternal and birth characteristics
Total cohort Alspac DNBC FINNPEC GenR Lund
N¼219575 n¼13444 n¼83532 n¼1930 n¼8363 n¼545
Maternal age, years (mean, SD) 29.8 (4.7) 28.0 (5.0) 29.8 (4.4) 29.9 (5.4) 29.7 (5.3) 30.0 (5.0)
Parity, % 0 50.4 45 50.6 66.1 55.0 68.5
BMI, kg/m2 23.0 21.6 22.6 23.6 23.9 NA
(median, 90% range) (18.7–32.9) (17.6–30.7) (18.6–31.9) (19.1–34.4) (19.4–33.7) NA
Chronic hypertension, % yes 1.3 3.8 0.2 10.6 1.9 0.9
Gestational age birth, weeks 40.0 40.0 40.0 39.0 40.1 38.7
(median, 90% range) (36.0–42.0) (36.0–42.0) (37.0–42.0) (31.0-–42.0) (36.9–42.0) (29.2–41.7)
Birthweight, grams (mean, SD) 3547.5 (585.0) 3408.7 (551.5) 3574.3 (571.9) 3096.3 (861.6) 3411.9 (561.5) 3156.1 (866.2)
Fetal sex, % female 48.8 48.4 48.8 50.8 49.5 50.3
MoBa OPB PEPP PREDO SCOPE VIP
n¼98436 n¼472 n¼4274 n¼1032 n¼5573 n¼1974
Maternal age, years (mean, SD) 30.2 (4.6) 31.7 (4.9) 26.3 (6.3) 32.3 (5.8) 28.7 (5.5) 30.8 (5.9)
Parity, % 0 46.7 53.8 68.1 31.8 100 49.9
BMI, kg/m2 23.1 23.9 24.1 25.5 24.2 31.2
(median, 90% range) (18.9–32.5) (19.1–35.9) (18.1–39.2) (19.1–39.5) (19.5–34.7) (21.1–43.4)
Chronic hypertension, % yes 0.5 0.2 2.5 18.4 2.7 41.0
Gestational age birth, weeks 40.0 38.4 39.0 39.9 40.1 39.0
(median, 90% range) (37.0–42.0) (28.6–40.3) (33.0–41.0) (36.4–41.9) (36.6–41.7) (33.1–41.9)
Birthweight, grams (mean, SD) 3600.3 (560.5) 3129.5 (1015.8) 3141.0 (728.3) 3510.7 (597.6) 3415.6 (555.4) 3217.7 (761.2)
Fetal sex, % female 48.7 50 49.2 46.6 49.2 49.1
NA, not available.
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Figure 1. Associations between fetal sex and overall PE between female and male pregnancies Results from random-effects models. Data reflect
Odds ratios (95% Confidence Interval) in which female preeclampsia (PE) is compared to male PE.
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Figure 2. Associations between fetal sex and term de novo PE between female and male pregnancies
Results from random-effects models. Data reflect Odds ratios (95% Confidence Interval) in which female term preeclampsia (PE) is compared to male
term PE. Term PE was defined as gestational age 37þ0 weeks at delivery.
International Journal of Epidemiology, 2017, Vol. 46, No. 2 637
Gestational age has been suggested as an indicator of
subsets of PE with a different pathophysiology and with
different acute and long-range outcomes for both mother
and baby. We hypothesize that perhaps we might be look-
ing at a biological phenomenon in which the observed sex-
specific differences reflect a functional placental difference
and subsequent response by the mother between the sexes
with differential PE phenotypes as a result.
So what underlies the sexual dimorphism in PE?
According to the two-stage model, impaired placentation
including dysfunctional remodelling of the utero-placental
arteries has been considered as powerful predisposing step
in the aetiology of PE. This has especially been suggested
for the early-onset subtype of PE.3,22 The first decidua-
associated remodelling step should be initiated around im-
plantation. Exposures at this stage might influence the risk
of PE. Previously, it was hypothesized by Vatten et al. that
a sex-specific susceptibility to the process of embryonic im-
plantation could partly explain sexual dimorphic differ-
ences in PE.5 The so-called ‘cross-over’ in the sex ratio of
PE was interpreted as an indication for the existence of
two separate pathogenetic entities. The first pathogenetic
entity would be associated with IUGR. Unfortunately, we
did not have information available on the occurrence of
IUGR to test this. The other pathogenetic entity proposed
was that late-onset disease originated from abnormal im-
plantation. Male embryos would be more susceptible to
suboptimal implantation or abnormal placental develop-
ment.23 This might imply that those pregnancies with a
male embryo that are susceptible to develop PE due to im-
paired placentation may already have miscarried in the
first trimester. The male fetuses that survive the period of
placentation will thereby represent a relatively healthy
group of fetuses leading to a female-biased prevalence of
PE. Orzsack et al.24 showed higher first-trimester male
miscarriage rates.24 Furthermore, lower first-trimester
human chorionic gonadotrophin hormone concentrations
(hCG) have been described for pregnancies with a male
fetus compared with pregnancies with a female fetus.25
Since progesterone levels are higher in male fetuses and
exert an inhibitory effect on hCG production, this may re-
sult in a lower hCG production by the male placenta and
thereby results in a differential endometrial receptivity.26
HCG is proposed to promote angiogenesis in the uterine
vasculature and to block any immunological action by the
mother on foreign invading placental cells.27 This might
also be related to earlier reported observations on a posi-
tive correlation between hCG levels, hyperemesis gravida-
rum and early-onset PE and fetal sex. Hyperemesis
gravidarum is associated with higher levels of hCG and
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Figure 3. Associations between fetal sex and preterm de novo PE between female and male pregnancies
Results from random-effects models. Data reflect Odds ratios (95% Confidence Interval) in which female preterm preeclampsia (PE) is compared to
male preterm PE. Preterm PE was defined as gestational age< 37þ0 weeks at delivery.
638 International Journal of Epidemiology, 2017, Vol. 46, No. 2
with an increased risk of early-onset PE.28–30 The presence
of a female fetus is associated with hyperemesis.
The second stage of the two-stage model is associated
with an exaggerated endothelial activation and a general-
ized hyperinflammatory state.3,31,32 Episodes of placental
hypoxia or reperfusion result in oxidative stress, subse-
quent apoptotic and necrotic disruption of syncytial archi-
tecture and release of various components from the
intervillous space into the maternal circulation that stimu-
lates the production of inflammatory cytokines.3,33,34
Broere-Brown et al.21 previously showed that the placental
release of circulating angiogenic and fibrinolytic factors
differs according to fetal sex.35 They observed higher S-
Flt1, PAI-2 and PlGF blood concentrations in cases of fe-
male as compared with male placentas. In pregnancies
complicated by PE, spontaneous preterm birth or IUGR,
however, no fetal sex-specific differences were observed.
From this they concluded that perhaps other mechanisms
causing these complications dominated the fetal sex ef-
fect.35 Muralimanoharan et al.36 also presented evidence
of sexual dimorphism in placentas from male fetuses com-
pared with placentas from female foetuses, with higher lev-
els of inflammatory, hypoxia and apoptotic molecules in
males. This was observed in placental tissue of term pre-
eclamptic pregnancies and is consistent with Vatten et al.5
In addition, they reported that in an obesogenic environ-
ment, primary trophoblasts derived from placentas of fe-
male fetuses have higher sensitivity to inflammatory stress
compared with placentas of males. Interestingly, Minghetti
et al.37 when studying preterm births, showed other results
with higher umbilical cord blood levels of the oxidative
stress biomarker 8-iso-PGF2a in male fetuses compared
with female fetuses, using a natural twinning model.37
Isoprostanes are free radical-catalyzed prostaglandin-like
products and considered as reliable markers of oxidative
stress. In line with this, Yeganegi et al.38 and Challis
et al.39 also demonstrated greater pro-inflammatory re-
sponses with a male fetus versus higher anti-inflammatory
responses in pregnancies with a female fetus. They sug-
gested that the male fetus exists in a relatively more ‘pro-
inflammatory environment’ than the female fetus. This
could account for the increased loss by miscarriage and
spontaneous preterm birth with male fetuses. However,
these latter three studies focused on preterm births in non-
pre-eclamptic pregnancies and thereby are not completely
pertinent to the distinct and multi-step entity of PE. We hy-
pothesize that differences between pregnancies with male
and female fetuses in the first (placental) but also second
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(systemic maternal) stage predispose to dimorphic differ-
ences in PE. Perhaps as previously suggested by Haig,40 PE
is a disorder of failed interaction between two genetically
different organisms. As PE is associated with long-term
maternal health and in view of increasing interest in micro-
chimerism (i.e. the long-term presence within an individual
of a low level of cells derived from a different individual),
the observed sexual dimorphic differences in the occur-
rence of PE might not be pertinent to pregnancy alone but
also might have important long-term cardiovascular health
implications for the mother.2,4
Strengths and limitations
We performed a large meta-analysis with individual data
from 11 studies participating in the CoLab consortium.
We did not rely on published data, which limits any poten-
tial publication bias. The large number of participants
enabled us to assess small effects. We presented results
from random-effects models which allow heterogeneity in
the true effect estimates between different populations and
take between-study variation into account. By applying the
leave-one-out method, we were able to determine the influ-
ence of any particular cohort on overall results. In agree-
ment with other studies, we used the dating of gestational
age at delivery as a proxy for the onset of PE, and not the
time of first diagnosis. In a small subset of women
(n¼ 1716) however, we did have information available on
actual gestational age at PE diagnosis. These data were
highly correlated with gestational age at birth (r¼0.89,
P< 0.001). We therefore think it is unlikely that non-
differential misclassification affected our effect estimates
greatly.
Finally, we chose to exclude stillbirths since some stud-
ies did only include live-born infants whereas in other stud-
ies the presence of stillbirths could have been under-
sampled (due to participation bias or loss-to-follow-up
bias). Some stillbirths might have occurred before PE has
been recognized clinically, or fetal sex may not have been
determined in some of the very early stillbirths. Vatten
et al.5 showed an increased risk of perinatal death in pre-
eclamptic pregnancies in case of male fetuses. We had in-
formation available on 660 stillbirths. Additional analyses,
however, in this subgroup showed no differences in the fe-
male/male distribution.
Conclusion
In conclusion we found that there are fetal sex-specific dif-
ferences in the occurrence of PE with a female dominance
among preterm, but not term, pregnancies complicated by
PE. Our results highlight the importance of fetal sex when
studying placenta-mediated-diseases.
Supplementary Data
Supplementary data are available at IJE online.
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